Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Host immunology and rational immunotherapy for carbapenem-resistant Klebsiella pneumoniae infection
Naoki Iwanaga, … , Kejing Song, Jay K. Kolls
Naoki Iwanaga, … , Kejing Song, Jay K. Kolls
Published March 26, 2020
Citation Information: JCI Insight. 2020;5(8):e135591. https://doi.org/10.1172/jci.insight.135591.
View: Text | PDF
Research Article Infectious disease Pulmonology

Host immunology and rational immunotherapy for carbapenem-resistant Klebsiella pneumoniae infection

  • Text
  • PDF
Abstract

Infections due to carbapenem-resistant Klebsiella pneumoniae have emerged as a global threat due to its widespread antimicrobial resistance. Transplant recipients and patients with hematologic malignancies have high mortality rate, suggesting host factors in susceptibility. We developed a model of pulmonary infection using ST258 strain C4, KPC-2 clone, which are predominant K. pneumoniae carbapenemase–producing (KPC-producing) bacteria, and demonstrated that Rag2–/– Il2rg–/– mice — but not WT C57BL/6 or Rag2–/– mice — were susceptible to this opportunistic infection. Using single cell RNA sequencing in infected Rag2–/– mice, we identified distinct clusters of Ifng+ NK cells and Il17a+, Il22+, and inducible T cell costimulatory molecule–positive (ICOS+) group 3 innate lymphoid cells (ILCs) that were critical for host resistance. As solid organ transplantation is a risk factor, we generated a more clinically relevant model using FK506 in WT C57BL/6 mice. We further demonstrated that immunotherapy with recombinant IL-22 treatment ameliorated the ST258 pulmonary infection in both FK506-treated WT mice and Rag2–/– Il2rg–/– mice via hepatic IL-22ra1 signaling. These data support the development of host-directed immunotherapy as an adjunct treatment to new antibiotics.

Authors

Naoki Iwanaga, Ivy Sandquist, Alanna Wanek, Janet McCombs, Kejing Song, Jay K. Kolls

×

Full Text PDF

Download PDF (3.84 MB)

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts